PAVmed (PAVM) Q3 2025 earnings summary

Executive summary

• Stabilized corporate structure and balance sheet through debt restructuring, subsidiary deconsolidation, and a $27 million public offering, positioning for future growth.

• Operating as a diversified life sciences company with independently financed subsidiaries, focusing on diagnostics and digital health.

• Lucid Diagnostics processed 2,841 EsoGuard tests, recognized $1.2 million in Q3 2025 revenue, and received unanimous Medicare CAC support for coverage.

• Veris Health launched a commercial partnership with OSU, advanced its implantable device toward a 2026 FDA submission, and expanded its cancer care platform.

• Signed a letter of intent to license endoscopic esophageal imaging technology, expanding the innovation pipeline.

Significant events and developments

• Lucid Diagnostics achieved a successful Medicare contractor meeting, with unanimous expert endorsement for EsoGuard coverage.

• Veris Health launched the commercial phase of its OSU partnership and relaunched implantable monitor development.

• Lucid Diagnostics was deconsolidated in September 2024, resulting in a one-time gain and a shift to equity method accounting.

• Series C Preferred Stock was issued in exchange for convertible notes, with waivers and conversion price reductions during 2025.

• Signed LOI to license endoscopic esophageal imaging technology from Duke University.

Segment performance

• Lucid Diagnostics generated $1.2 million in revenue from 2,841 EsoGuard tests in Q3 2025.

• Veris Health expanded commercial activities, relaunched device development, and focused on AI-based clinical decision tools.

• Post-deconsolidation, operations focus on Veris Health and management services for Lucid; Lucid is now an equity method investment valued at $31.6 million.